Wells Fargo & Company MN Has $12.18 Million Position in Anika Therapeutics Inc. (ANIK)

Wells Fargo & Company MN boosted its holdings in Anika Therapeutics Inc. (NASDAQ:ANIK) by 25.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 209,928 shares of the biotechnology company’s stock after acquiring an additional 42,015 shares during the quarter. Wells Fargo & Company MN owned 1.43% of Anika Therapeutics worth $12,176,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. The Manufacturers Life Insurance Company boosted its stake in Anika Therapeutics by 0.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,227 shares of the biotechnology company’s stock valued at $554,000 after purchasing an additional 89 shares in the last quarter. Rhumbline Advisers boosted its stake in Anika Therapeutics by 0.3% during the 2nd quarter. Rhumbline Advisers now owns 27,720 shares of the biotechnology company’s stock valued at $1,368,000 after purchasing an additional 96 shares in the last quarter. CS Mckee LP boosted its stake in Anika Therapeutics by 0.7% during the 2nd quarter. CS Mckee LP now owns 14,100 shares of the biotechnology company’s stock valued at $696,000 after purchasing an additional 100 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its stake in Anika Therapeutics by 0.5% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 20,186 shares of the biotechnology company’s stock valued at $996,000 after purchasing an additional 100 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in Anika Therapeutics by 1.3% during the 2nd quarter. Arizona State Retirement System now owns 7,690 shares of the biotechnology company’s stock valued at $379,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 84.91% of the company’s stock.

A number of equities analysts have issued reports on the company. Barrington Research increased their price target on Anika Therapeutics from $53.00 to $57.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. BidaskClub lowered Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 14th.

Shares of Anika Therapeutics Inc. (ANIK) opened at $52.22 on Monday. The firm has a market capitalization of $764.47, a price-to-earnings ratio of 24.52, a PEG ratio of 2.74 and a beta of 1.46. Anika Therapeutics Inc. has a one year low of $41.64 and a one year high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.05. The business had revenue of $27.18 million during the quarter, compared to analyst estimates of $27.44 million. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $0.59 EPS. sell-side analysts anticipate that Anika Therapeutics Inc. will post 1.9 EPS for the current year.

In other news, CEO Charles H. Sherwood sold 3,293 shares of the firm’s stock in a transaction on Monday, October 16th. The stock was sold at an average price of $60.04, for a total transaction of $197,711.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Charles H. Sherwood sold 22,228 shares of the firm’s stock in a transaction on Monday, October 23rd. The stock was sold at an average price of $60.06, for a total value of $1,335,013.68. Following the sale, the chief executive officer now directly owns 158,297 shares of the company’s stock, valued at $9,507,317.82. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,886 shares of company stock valued at $2,606,455. Corporate insiders own 6.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Wells Fargo & Company MN Has $12.18 Million Position in Anika Therapeutics Inc. (ANIK)” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://www.com-unik.info/2017/12/25/wells-fargo-company-mn-has-12-18-million-position-in-anika-therapeutics-inc-anik.html.

Anika Therapeutics Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit